Literature DB >> 18270672

[Management of hemostasis disorders after extracorporeal circulation. A clinical therapy algorithm].

C Jámbor1, D Bremerich, A Moritz, E Seifried, B Zwissler.   

Abstract

After cardiac surgery with extracorporeal circulation, approximately 20% of patients show significant bleeding tendencies and 5% require re-intervention. In 50% of patients undergoing re-operation, no surgical cause can be determined, suggesting coagulopathy after cardiopulmonary bypass (CPB). For perioperative management of transfusion of blood products and coagulation factor concentrates, a clinical algorithm for the perioperative hemostatic therapy in patients undergoing cardiac surgery with CPB has been developed. The currently available evidence and the point of care methods routinely accessible in our institution (blood gas analysis, ACT, point of care Quick value, aPTT and platelet count) were used. The intervention with plasma products, coagulation factor concentrates and hemostatic drugs after extracorporeal circulation are described. Extensive bleeding history as well as the efficacy and side effects of antifibrinolytic treatment are discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18270672     DOI: 10.1007/s00101-008-1336-8

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  39 in total

1.  Assessing platelet and fibrinogen contribution to clot strength using modified thromboelastography in pregnant women.

Authors:  V N Gottumukkala; S K Sharma; J Philip
Journal:  Anesth Analg       Date:  1999-12       Impact factor: 5.108

2.  Antifibrinolytic therapy: treat whom and with what?

Authors:  J C Horrow
Journal:  J Clin Anesth       Date:  1995-12       Impact factor: 9.452

3.  Influence of desmopressin acetate on homologous blood requirements in cardiac surgical patients pretreated with aspirin.

Authors:  G Dilthey; W Dietrich; M Spannagl; J A Richter
Journal:  J Cardiothorac Vasc Anesth       Date:  1993-08       Impact factor: 2.628

4.  A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery.

Authors:  Keyvan Karkouti; W Scott Beattie; Kathleen M Dattilo; Stuart A McCluskey; Mohammed Ghannam; Ahmed Hamdy; Duminda N Wijeysundera; Ludwik Fedorko; Terrence M Yau
Journal:  Transfusion       Date:  2006-03       Impact factor: 3.157

5.  Dextran and hydroxyethyl starch interfere with fibrinogen assays.

Authors:  S T Hiippala
Journal:  Blood Coagul Fibrinolysis       Date:  1995-12       Impact factor: 1.276

Review 6.  Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials.

Authors:  S J Stanworth; S J Brunskill; C J Hyde; D B L McClelland; M F Murphy
Journal:  Br J Haematol       Date:  2004-07       Impact factor: 6.998

7.  Acquired von Willebrand syndrome in aortic stenosis.

Authors:  André Vincentelli; Sophie Susen; Thierry Le Tourneau; Isabelle Six; Olivier Fabre; Francis Juthier; Anne Bauters; Christophe Decoene; Jenny Goudemand; Alain Prat; Brigitte Jude
Journal:  N Engl J Med       Date:  2003-07-24       Impact factor: 91.245

8.  A practical concept for preoperative management of patients with impaired primary hemostasis.

Authors:  Juergen Koscielny; Georg-Friedrich von Tempelhoff; Sabine Ziemer; Hartmut Radtke; Michael Schmutzler; Pranav Sinha; Abdulgabar Salama; Holger Kiesewetter; Reinhard Latza
Journal:  Clin Appl Thromb Hemost       Date:  2004-04       Impact factor: 2.389

9.  Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass.

Authors:  T Mochizuki; P J Olson; F Szlam; J G Ramsay; J H Levy
Journal:  Anesth Analg       Date:  1998-10       Impact factor: 5.108

10.  Hemostasis and hemodilution: a quantitative mathematical guide for clinical practice.

Authors:  Kai Singbartl; Petra Innerhofer; Jens Radvan; Birgit Westphalen; Dietmar Fries; Raimund Stögbauer; Hugo Van Aken
Journal:  Anesth Analg       Date:  2003-04       Impact factor: 5.108

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.